OncoMatch/Clinical Trials/NCT06488222

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Is NCT06488222 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Docetaxel and Gemcitabine for bladder cancer.

Treatment: Docetaxel · Gemcitabine — Bladder cancer is the 8th most common cancer in the UF Health Cancer Center catchment area and the 7th most common cancer presenting to UFHealth. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle invasion and no evidence of disease beyond the bladder. The current use in BCG (Bacillus Calmette-Guerin) refractory disease and the ongoing evaluation in BCG naïve high-risk disease support evaluation of intravesical gemcitabine and docetaxel in decreasing disease recurrence in intermediate risk stage I bladder cancer. This study will investigate the efficacy and subject compliance with treatment of low grade intermediate risk bladder cancer with intravesical gemcitabine and docetaxel.